- As of closing April 2, Xencor is trading nearly 30% below the mean target of $16.30 and 20% below its 52wk high of $13.90 in mid-march before the recent disruption.
- Their bispecific antibody (bAb) leads are very promising, uniquely allowing fine tuning of pharmacokinetic parameters against a given target. bAb are forecast to account for $4.4bn in sales by 2023.
- Xencor’s diverse and patent protected Fc domains can be simply licensed and will provide a steady stream of revenue with which the company can clinically develop in-house leads.
- Antibody biologics are on fire, making up 6/20 top-selling drugs and $50bn in 2012. Xencor has a diverse lead portfolio and strong management, promising a piece of the action soon.